Celldex Therapeutics (CLDX) Short term Debt (2010 - 2013)

Celldex Therapeutics' Short term Debt history runs 4 years deep, the most recent figure standing at $5.6 million for Q1 2013.

• In Q1 2013, Short term Debt rose 6.35% year-over-year to $5.6 million; the TTM figure through Mar 2013 stood at $5.6 million (up 6.35% YoY), while the FY2012 annual figure was $5.6 million, down 8.87% from the prior year.
• Short term Debt for Q1 2013 stood at $5.6 million, up from $5.6 million in the prior quarter.
• The five-year high for Short term Debt was $6.1 million in Q4 2011, with the low at $1.1 million in Q4 2010.
• The 4-year median for Short term Debt is $5.3 million (2012), against an average of $4.8 million.
• The sharpest annual moves came in 2011 and 2012: Short term Debt jumped 452.3% in 2011, then slipped 8.87% in 2012.
• Celldex Therapeutics' Short term Debt stood at $1.1 million in 2010, then surged by 452.3% to $6.1 million in 2011, then retreated by 8.87% to $5.6 million in 2012, then climbed by 0.68% to $5.6 million in 2013.
• Business Quant data shows CLDX's Short term Debt at $5.6 million in Q1 2013, $5.6 million in Q4 2012, and $5.3 million in Q3 2012.